This study, to our knowledge, is the first to report that harboring a combination of variants in the KRAS, LRP1B and TP53 can clearly be beneficial for the response to ICB and could be considered a potential predictive biomarker for NSCLC patients. Here, KRAS is linked to non-small cell lung carcinoma.